02.06.2013 Views

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

16 ALISKIREN<br />

ALISKIREN<br />

Trade name: Tekturna (Novartis)<br />

Indications: Hypertension<br />

Half-life: 24 hours<br />

Clinically important, potentially hazardous interactions<br />

with: furosemide, ketoconazole<br />

Reactions<br />

Skin<br />

Angioedema<br />

Rash (sic) (1%)<br />

Eyes<br />

Periorbital edema<br />

Other<br />

Abdominal pain<br />

Cough<br />

(2006): Vaidyanathan S+, Int J Clin Pract 60(11), 1343<br />

ALITRETINOIN<br />

Trade name: Panretin (Lig<strong>and</strong>)<br />

Indications: Kaposi’s sarcoma cutaneous lesions<br />

Category: Retinoid<br />

Half-life: N/A<br />

Reactions<br />

Skin<br />

Abrasion<br />

Adverse effects (sic)<br />

(2000): Duvic M+, Arch Dermatol 136, 1461 (17%)<br />

Bullous dermatitis<br />

Burning<br />

(2002): Morganroth GS, Arch Dermatol 138, 542<br />

Edema (3–8%)<br />

(2000): Duvic M+, Arch Dermatol 136, 1461 (3%)<br />

Exfoliative dermatitis (3–9%)<br />

Photosensitivity<br />

Pigmentation (3%)<br />

(2000): Duvic M+, Arch Dermatol 136, 1461 (3%)<br />

Pruritus (8–11%)<br />

Rash (sic) (25–77%)<br />

(2000): Duvic M+, Arch Dermatol 136, 1461 (69%)<br />

Toxicity (sic)<br />

(2002): Miles SA+, AIDS 16(3), 421<br />

Ulcerations (2%)<br />

(2000): Duvic M+, Arch Dermatol 136, 1461<br />

Xerosis (10%)<br />

(2000): Duvic M+, Arch Dermatol 136, 1461 (10%)<br />

Hair<br />

Hair – alopecia<br />

Other<br />

Application-site dermatitis<br />

(2002): Morganroth GS, Arch Dermatol 138, 542<br />

Application-site reactions<br />

(1999): Walmsley S+, J Acquir Immune Defic Syndr 22, 325<br />

Myalgia/Myositis/Myopathy/Myotoxicity<br />

Pain<br />

(2000): Duvic M+, Arch Dermatol 136, 1461 (18%)<br />

ALLOPURINOL<br />

Trade names: Allo 300; Allo-Puren; Alloprin; Atisuril; Bleminol;<br />

Caplenal; Hamarin; Novo-Purol; Purinol; Unizuric; Zyloprim<br />

(Prometheus); Zyloric<br />

Indications: Gouty arthritis<br />

Category: Purine analog; Xanthine oxidase inhibitor<br />

Half-life: 1–3 hours<br />

Clinically important, potentially hazardous interactions<br />

with: amoxicillin, ampicillin, azathioprine, dicumarol,<br />

mercaptopurine, pantoprazole, uracil/tegafur, vidarabine<br />

Reactions<br />

Skin<br />

Acute generalized exanthematous pustulosis (AGEP)<br />

(2002): Lun K+, Australas J Dermatol 43(2), 140<br />

(1995): Moreau A+, Int J Dermatol 34, 263 (passim)<br />

Adverse effects (sic)<br />

(2006): Ch<strong>and</strong>eclerc ML+, Allergy 61(12), 1492<br />

(2003): Chubar Y+, Br J Haematol 122(5), 768<br />

Allergic reactions (sic) (severe)<br />

(1999): Tanna SB+, Ann Pharmacother 33, 1180<br />

Angioedema<br />

(1996): Yale SH+, Hosp Pract Off Ed 31, 92<br />

Diaphoresis (

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!